Clinical Trial Update: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing nelipepimut-S plus GM-CSF vaccine therapy for breast ductal carcinoma in situ has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Ductal Carcinoma in Situ

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• nelipepimut-S (nelipepimut-S)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Ductal Carcinoma In Situ | Phase 2 | Status: COMPLETED | Results posted: 2023-05-16